Opinion

Video

EHA 2024 Highlights: Overcoming Challenges with Bispecific Antibodies in RRMM

Author(s):

Joseph Mikhael, MD

Dr. Mikhael outlines the significant hurdles in bispecific antibody therapy, as presented at the European Hematology Association's 2024 conference.

Video content above is prompted by the following question:

  1. Results from the phase 1/2 MonumenTAL-1 study and phase 1B MonumenTAL-2 study were also presented at EHA 2024. How do the results from these two trials contribute to the evolving role of talquetamab in multiple myeloma?
  2. What is the value of long-term follow-up data in multiple myeloma? How does this impact use of treatment regimens?
  3. What challenges must be considered and overcome with bispecific antibody-containing regimens in RRMM?
Related Videos
Leland Metheny, MD, University Hospitals Seidman Cancer Center
Jason Porter, MD, an expert on lung cancer
1 KOL is featured in this program.
1 KOL is featured in this program.
Joseph Mikhael, MD, an expert on multiple myeloma
Jason Porter, MD, an expert on lung cancer
Jason Porter, MD, an expert on lung cancer
Alfred L. Garfall, MD, an expert on multiple myeloma
Alfred L. Garfall, MD, an expert on multiple myeloma
Joseph Mikhael, MD, an expert on multiple myeloma
Related Content
Leland Metheny, MD, University Hospitals Seidman Cancer Center
August 30th 2024

Triple-Target CAR T Cells: Benefits and Challenges

Maggie L. Shaw
In part 1 of our interview with Leland Metheny, MD, he explained how a new triple-target chimeric antigen receptor (CAR) T-cell therapy works in multiple myeloma.
Regeneron logo | Image credit: Casimiro – stock.adobe.com
August 21st 2024

FDA Issues CRL for Linvoseltamab in R/R Multiple Myeloma

Hayden E. Klein
The complete response letter (CRL) was issued based on a pre-approval inspection at a third-party fill/finish manufacturer.
stem cells | Image Credit: jarun011-stock.adobe.com
August 20th 2024

Second ASCT Extends Survival in Relapsed Multiple Myeloma

Maggie L. Shaw
To continue the response they experienced with a first autologous stem‐cell transplant (ASCT) for their multiple myeloma, patients in this analysis received a second ASCT, with French investigators evaluating their outcomes.
MM treatment | Image Credit: Dzmitry-stock.adobe.com
August 14th 2024

Challenges With Pomalidomide for Patients With Comorbid RRMM, CKD

Maggie L. Shaw
Patients who have comorbid relapsed/refractory multiple myeloma (RRMM) and advanced chronic kidney disease (CKD) are often excluded from clinical trials, leaving treatment gaps for these high-risk patients.
MM blood test | Image Credit: luchschenF-stock.adobe.com
August 6th 2024

Novel Therapies Needed for Older Patients With RRMM

Maggie L. Shaw
Relapsed/refractory multiple myeloma (RRMM) remains an incurable hematologic cancer, often resulting in patients treated with several classes of medications—particularly older patients.
FDA | Image Credit: ra2studio-stock.adobe.com
July 31st 2024

Daratumumab and Hyaluronidase-fihj–Based Quadruplet Regimen Approved in MM

Maggie L. Shaw
Daratumumab/hyaluronidase-fihj plus bortezomib, lenalidomide, and dexamethasone is now approved by the FDA to treat newly diagnosed multiple myeloma (MM) in patients eligible for autologous stem cell transplant.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo